Companion Diagnostics Market 2025–2035: Regional Insights, Growth Drivers, and Forecast

Last Updated:2026年4月24日
Publish Date:2026年4月24日
Base Year:2026
Format:
Industry - Biotechnology
Forecast Period:2025-2035
Report ID:SYNRPT1611653
Number Of Pages:
TOC:TOC included

Introduction

The global companion diagnostics market is projected to grow from 2025 to 2035, driven by the rise of personalized medicine, biomarker identification, and targeted therapies. Advanced diagnostic assays are being increasingly integrated into clinical workflows to optimize patient outcomes. According to the “Global Companion Diagnostics Market 2025–2035” report by Synapsea Global, the study explores trends, regulatory landscapes, and investment opportunities for diagnostics companies and healthcare providers.

Key Report Highlights

Projected Growth: The companion diagnostics market is expected to witness a CAGR of 10.5%, achieving $27 Billion by 2035.

Dominant Segments

The Fetal Bovine Serum Market is led by in vitro research-grade serum, used in cell culture applications. Rising demand in biotechnology and regenerative medicine research supports growth.

Competitive Intelligence

In the Companion Diagnostics Market, competition is shaped by biomarker discovery, precision medicine alignment, and integration with targeted therapies. Firms enhance differentiation through collaborations with pharmaceutical companies and adherence to stringent regulatory standards.

Strategic Insights

In the Companion Diagnostics Market, integrating personalized medicine approaches, strengthening partnerships with pharmaceutical companies, and advancing biomarker discovery enhance growth prospects. Regulatory compliance and precision-focused solutions increase clinical adoption and reliability.

Regional Dynamics

The Companion Diagnostics Market is dominated by North America, supported by precision medicine adoption and healthcare infrastructure. Europe follows with strong oncology diagnostics penetration, and Asia-Pacific shows fastest growth. Latin America and MEA are emerging regions.

Rising Precision Medicine Adoption, Targeted Therapy Expansion & Oncology Advancements: Why Our Companion Diagnostics Market Report is Essential for Modern Healthcare Growth

The global companion diagnostics market is experiencing rapid growth, driven by the increasing adoption of personalized medicine, rising prevalence of cancer and chronic diseases, and growing demand for targeted therapies. Companion diagnostics are tests or assays that help identify patients who are most likely to benefit from a specific drug or treatment, ensuring improved therapeutic outcomes and reduced adverse effects.

Pharmaceutical companies are increasingly collaborating with diagnostic developers to co-develop drug-diagnostic combinations, particularly in oncology and immunotherapy. Technological advancements in molecular diagnostics, next-generation sequencing (NGS), and biomarker identification are further accelerating market expansion.

Image of Datacenter

1. By Technology: Polymerase Chain Reaction (PCR) (Dominant Segment)

PCR-based technologies hold the largest market share globally.

Why it dominates:

  • High accuracy and sensitivity in detecting genetic mutations
  • Widely used in oncology and infectious disease testing
  • Cost-effective compared to advanced sequencing methods
  • Fast turnaround time for diagnostic results

2. By Application: Oncology (Dominant Segment)

Oncology remains the leading application area.

Why:

  • Rising global cancer incidence
  • Strong demand for targeted cancer therapies
  • Increasing use of biomarker-based treatment decisions
  • Growing number of cancer drug approvals linked with diagnostics

3. By Type: Assays & Kits (Dominant Segment)

Assays and diagnostic kits dominate the market.

Why:

  • Easy-to-use and standardized testing solutions
  • High demand in clinical laboratories and hospitals
  • Rapid commercialization of approved companion tests
  • Widespread adoption in routine diagnostics

4. By End User: Pharmaceutical & Biopharmaceutical Companies (Dominant Segment)

Pharmaceutical and biopharmaceutical companies are key end users.

Why:

  • Strong focus on drug-diagnostic co-development
  • Increasing investment in precision medicine pipelines
  • Growing number of clinical trials requiring biomarkers
  • Strategic partnerships with diagnostic manufacturers

5. By Geography: North America (Dominant Region)

North America leads the companion diagnostics market.

Key factors:

  • Advanced healthcare infrastructure and diagnostic labs
  • High adoption of precision medicine approaches
  • Strong presence of leading pharmaceutical and biotech companies
  • Supportive regulatory framework for companion diagnostics approvals

Fastest-growing region:

  • Asia-Pacific
Image of Datacenter

Drivers: What is fueling market growth?

  • Rising demand for personalized and precision medicine
  • Increasing prevalence of cancer and chronic diseases
  • Growing use of targeted therapies and biologics
  • Advancements in biomarker discovery and genomics
  • Expansion of clinical trials requiring companion diagnostics

Restraints (R) – What is limiting growth?

  • High cost of diagnostic test development and validation
  • Complex regulatory approval processes
  • Limited reimbursement in some regions
  • Need for specialized infrastructure and skilled professionals

Opportunities (O) – Where is future growth coming from?

  • Expansion of next-generation sequencing-based diagnostics
  • Growth in oncology-focused companion diagnostic development
  • Increasing pharma-diagnostic partnerships
  • Adoption of AI in biomarker identification and analysis

Trends (T) – What is shaping the future?

  • Rise of multi-biomarker and multiplex testing
  • Integration of genomics and proteomics in diagnostics
  • Growth in liquid biopsy-based companion diagnostics
  • Increasing focus on real-time treatment monitoring tools
Image of Datacenter

Market Scope & Analysis

ATTRIBUTE
DETAILS
Study Period
2021-2034
Market Base Year
2026
Estimated Year
2026
Forecast Period
2025-2035
Historical Period
2021-2024
Growth Rate
CAGR of 10.5%
Market size value in 2025
$10 Billion
Market size value by 2035
$27 Billion
Segmentation Covered

1. By Technology

  • PCR (Polymerase Chain Reaction)
  • Next-Generation Sequencing (NGS)
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)

2. By Application

  • Oncology
  • Cardiology
  • Neurology
  • Infectious Diseases

3. By Type

  • Assays & Kits
  • Instruments
  • Software & Services

4. By End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Hospitals & Diagnostic Laboratories
  • Research & Academic Institutes

5. By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa
Market Leaders
Market Leaders
  • Roche
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • QIAGEN
  • Agilent Technologies
Regions & Countries Covered
Regions & Countries Covered
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East
  • Africa
  • United States
  • Canada
  • Germany
  • United Kingdom
  • France
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Brazil
  • Mexico
  • United Arab Emirates
  • Saudi Arabia

Recent Developments

Recent Developments

October 2024: Roche partnered with a leading pharmaceutical company to co‑develop companion diagnostics for a new targeted oncology therapy expected to launch in 2025.

May 2025: Abbott Laboratories released a next‑generation companion diagnostic platform that integrates AI‑based analysis to improve patient stratification in clinical settings.

FAQ

A1: The global companion diagnostics market is forecasted to grow at a CAGR of 10.5% between 2025 and 2035, fueled by personalized medicine demand.

A2: Oncology, personalized medicine, and targeted therapy selection are driving the most growth within the companion diagnostics market.

A3: The key players in Companion Diagnostics Market are – Roche, Abbott Laboratories, Thermo Fisher Scientific, QIAGEN, and Agilent Technologies.

A4: Complex regulatory landscape, high cost, and reimbursement issues slow companion diagnostics adoption.

A5: Companion diagnostics market grows fastest in North America with increasing personalized medicine adoption.

A6: Companion diagnostics market verticals include oncology, infectious diseases, cardiology, personalized medicine, and rare diseases.

Seize Tomorrow's Opportunities Today: Access the Full Report

Personalize This Report

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Digital Health Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Customized Workshop Request